RwandaTuberculosis profile
Population  2015 12 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.44 (0.26–0.67) 3.8 (2.2–5.8)
Mortality (HIV+TB only) 0.28 (0.01–0.97) 2.4 (0.09–8.3)
Incidence  (includes HIV+TB) 6.6 (5.6–7.6) 56 (48–65)
Incidence (HIV+TB only) 1.8 (1.1–2.5) 15 (9.8–22)
Incidence (MDR/RR-TB)** 0.16 (0.1–0.21) 1.4 (0.86–1.8)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.41 (0.24–0.59) 1.9 (1.2–2.6) 2.3 (1.4–3.2)
Males 0.43 (0.29–0.56) 3.8 (3–4.7) 4.3 (3.3–5.2)
Total 0.84 (0.63–1.1) 5.7 (5.1–6.3) 6.6 (5.6–7.6)
TB case notifications, 2015  
Total cases notified 5 637
Total new and relapse 5 534
          - % tested with rapid diagnostics at time of diagnosis 39%
          - % with known HIV status 96%
          - % pulmonary 86%
          - % bacteriologically confirmed among pulmonary 86%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 84% (73–99)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.11 (0.04–0.21)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 1 450 27%
          - on antiretroviral therapy 1 237 85%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  120
(73–180)
Estimated % of TB cases with MDR/RR-TB 1.5% (0.77–2.2) 11% (3.3–18)  
% notified tested for rifampicin resistance 26% 19% 1 644
MDR/RR-TB cases tested for resistance to second-line drugs   24
Laboratory-confirmed cases MDR/RR-TB: 94, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 93, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 86% 5 846
Previously treated cases, excluding relapse, registered in 2014 80% 94
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013 81% 43
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
74% (68–81)
TB financing, 2016  
National TB budget (US$ millions) 15
Funding source: 21% domestic, 60% international, 19% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-06 Data: www.who.int/tb/data